Senti Streamline Their CAR-NK Cell Therapy Program to Focus on Acute Myeloid Leukaemia
Senti Biosciences has moved one of its drug candidates to the backburner to focus on two remaining CAR-NK cell therapy programs.
The biotech company, based in San Francisco, has shelved the development of SENTI-301A – a CAR-NK (chimeric antigen receptor – natural killer) cell therapy developed to target hepatocellular carcinoma, one of the most common types of liver cancer.
In a press release, Senti stated that they “do not intend to invest in the clinical development of SENTI-301A, for the treatment of hepatocarcinoma (HCC) on its own at this time.”
By streamlining their research, Senti will be giving more focus to its other ongoing oncology programs, SENTI-202 and SENTI-401.
The former, SENTI-202, is an off-the-shelf product candidate designed to target and eliminate acute myeloid leukaemia (AML) while sparing healthy bone marrow.
SENTI-202 is currently on its way to the clinic, with Senti running final studies ahead of a planned IND filing for the CAR-NK cell therapy in the second half of the year.
With this measure, Senti expects its current financial reserves to last through to at least the first quarter of 2024.
ارسال به دوستان